Intended for U.S. audiences only.
Governance & Compliance
Healthcare Professionals
News
Contact Us
HOME
ABOUT US
PRODUCTS
CAREERS
News
April 20, 2026
Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
April 07, 2025
Luye Pharma Announces U.S. Launch of ERZOFRI
®
(paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
January 14, 2025
Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.
Read More
